Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Rudin

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
The Lancet. Rheumatology|March 25, 2026
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trialJon Lampa, Dan Nordström, Ronald van Vollenhoven, et al.
Annals of the Rheumatic Diseases|July 9, 2023
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trialMikkel Østergaard, Ronald F van Vollenhoven, Anna Rudin, et al.
Rheumatology (Oxford, England)|December 6, 2017
Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational StudySébastien Peytrignet, Christopher P Denton, Mark Lunt, et al.
Annals of the Rheumatic Diseases|February 12, 2017
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, et al.
Annals of the Rheumatic Diseases|January 8, 2018
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational StudyAriane L Herrick, Sebastien Peytrignet, Mark Lunt, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
The Lancet. Rheumatology|March 25, 2026
Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trialJon Lampa, Dan Nordström, Ronald van Vollenhoven, et al.
Annals of the Rheumatic Diseases|July 9, 2023
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trialMikkel Østergaard, Ronald F van Vollenhoven, Anna Rudin, et al.
Rheumatology (Oxford, England)|December 6, 2017
Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational StudySébastien Peytrignet, Christopher P Denton, Mark Lunt, et al.
Annals of the Rheumatic Diseases|February 12, 2017
Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS)Ariane L Herrick, Xiaoyan Pan, Sébastien Peytrignet, et al.
Annals of the Rheumatic Diseases|January 8, 2018
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational StudyAriane L Herrick, Sebastien Peytrignet, Mark Lunt, et al.
Pageof 10